{"id":"https://openalex.org/W2005449994","doi":"https://doi.org/10.1016/0014-2999(86)90775-2","title":"Response of mesolimbic substance P systems to methamphetamine treatment","display_name":"Response of mesolimbic substance P systems to methamphetamine treatment","publication_year":1986,"publication_date":"1986-09-01","ids":{"openalex":"https://openalex.org/W2005449994","doi":"https://doi.org/10.1016/0014-2999(86)90775-2","mag":"2005449994","pmid":"https://pubmed.ncbi.nlm.nih.gov/2431914"},"language":"en","primary_location":{"id":"doi:10.1016/0014-2999(86)90775-2","doi":"https://doi.org/10.1016/0014-2999(86)90775-2","is_oa":false,"landing_page_url":"https://doi.org/10.1016/0014-2999(86)90775-2","pdf_url":null,"source":{"id":"https://openalex.org/S187816532","display_name":"European Journal of Pharmacology","issn_l":"0014-2999","issn":["0014-2999","1879-0712"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-d","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European Journal of Pharmacology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5057713670","display_name":"Glen R. Hanson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I223532165","display_name":"University of Utah","ror":"https://ror.org/03r0ha626","country_code":"US","type":"education","lineage":["https://openalex.org/I223532165"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Glen R. Hanson","raw_affiliation_strings":["Department of Biochemical Pharmacology and Toxicology, University of Utah, Salt Lake City, UT 84112, U.S.A"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Biochemical Pharmacology and Toxicology, University of Utah, Salt Lake City, UT 84112, U.S.A","institution_ids":["https://openalex.org/I223532165"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063054979","display_name":"Joseph K. Ritter","orcid":"https://orcid.org/0000-0003-4028-8654","observed_orcids":["https://orcid.org/0000-0003-4028-8654"]},"institutions":[{"id":"https://openalex.org/I223532165","display_name":"University of Utah","ror":"https://ror.org/03r0ha626","country_code":"US","type":"education","lineage":["https://openalex.org/I223532165"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Joseph K. Ritter","raw_affiliation_strings":["Department of Biochemical Pharmacology and Toxicology, University of Utah, Salt Lake City, UT 84112, U.S.A"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Biochemical Pharmacology and Toxicology, University of Utah, Salt Lake City, UT 84112, U.S.A","institution_ids":["https://openalex.org/I223532165"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108749540","display_name":"Christopher J. Schmidt","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I223532165","display_name":"University of Utah","ror":"https://ror.org/03r0ha626","country_code":"US","type":"education","lineage":["https://openalex.org/I223532165"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Christopher J. Schmidt","raw_affiliation_strings":["Department of Biochemical Pharmacology and Toxicology, University of Utah, Salt Lake City, UT 84112, U.S.A"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Biochemical Pharmacology and Toxicology, University of Utah, Salt Lake City, UT 84112, U.S.A","institution_ids":["https://openalex.org/I223532165"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5074723102","display_name":"James W. Gibb","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I223532165","display_name":"University of Utah","ror":"https://ror.org/03r0ha626","country_code":"US","type":"education","lineage":["https://openalex.org/I223532165"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"James W. Gibb","raw_affiliation_strings":["Department of Biochemical Pharmacology and Toxicology, University of Utah, Salt Lake City, UT 84112, U.S.A"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Biochemical Pharmacology and Toxicology, University of Utah, Salt Lake City, UT 84112, U.S.A","institution_ids":["https://openalex.org/I223532165"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5057713670"],"corresponding_institution_ids":["https://openalex.org/I223532165"],"apc_list":{"value":3230,"currency":"USD","value_usd":3230},"apc_paid":null,"fwci":0.4199,"has_fulltext":false,"cited_by_count":12,"citation_normalized_percentile":{"value":0.49090552,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":93,"max":96},"biblio":{"volume":"128","issue":"3","first_page":"265","last_page":"268"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10056","display_name":"Neurotransmitter Receptor Influence on Behavior","score":0.5990999937057495,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10056","display_name":"Neurotransmitter Receptor Influence on Behavior","score":0.5990999937057495,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10814","display_name":"Neuropeptides and Animal Physiology","score":0.3889000117778778,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10077","display_name":"Neuroscience and Neuropharmacology Research","score":0.005100000184029341,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/methamphetamine","display_name":"methamphetamine","score":0.9520000219345093},{"id":"https://openalex.org/keywords/substance-p","display_name":"substance P","score":0.9990000128746033},{"id":"https://openalex.org/keywords/mesolimbic-pathway","display_name":"mesolimbic system","score":0.9800000190734863},{"id":"https://openalex.org/keywords/ventral-tegmental-area","display_name":"ventral tegmental area","score":0.9990000128746033},{"id":"https://openalex.org/keywords/medial-habenula","display_name":"medial habenula","score":0.9549999833106995},{"id":"https://openalex.org/keywords/repeated-dosing","display_name":"repeated dosing","score":0.515999972820282},{"id":"https://openalex.org/keywords/single-dose-effects","display_name":"single-dose effects","score":0.5839999914169312}],"concepts":[{"id":"https://openalex.org/C2780114369","wikidata":"https://www.wikidata.org/wiki/Q6823535","display_name":"Meth-","level":5,"score":0.9610531330108643},{"id":"https://openalex.org/C2780948874","wikidata":"https://www.wikidata.org/wiki/Q640562","display_name":"Ventral tegmental area","level":4,"score":0.9366608262062073},{"id":"https://openalex.org/C2780376393","wikidata":"https://www.wikidata.org/wiki/Q191924","display_name":"Methamphetamine","level":2,"score":0.8834999799728394},{"id":"https://openalex.org/C118303440","wikidata":"https://www.wikidata.org/wiki/Q419968","display_name":"Neuropeptide","level":3,"score":0.6675037741661072},{"id":"https://openalex.org/C2777650357","wikidata":"https://www.wikidata.org/wiki/Q1569460","display_name":"Mesolimbic pathway","level":5,"score":0.5445237159729004},{"id":"https://openalex.org/C2776533618","wikidata":"https://www.wikidata.org/wiki/Q411041","display_name":"Substance P","level":4,"score":0.5110291242599487},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.49683526158332825},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3825371563434601},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.37684327363967896},{"id":"https://openalex.org/C169760540","wikidata":"https://www.wikidata.org/wiki/Q207011","display_name":"Neuroscience","level":1,"score":0.3493645191192627},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.33319273591041565},{"id":"https://openalex.org/C513476851","wikidata":"https://www.wikidata.org/wiki/Q170304","display_name":"Dopamine","level":2,"score":0.3059348464012146},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.26391738653182983},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.2502877116203308},{"id":"https://openalex.org/C137183658","wikidata":"https://www.wikidata.org/wiki/Q461076","display_name":"Dopaminergic","level":3,"score":0.08205920457839966},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.045156627893447876},{"id":"https://openalex.org/C166940927","wikidata":"https://www.wikidata.org/wiki/Q178827","display_name":"Monomer","level":3,"score":0.0},{"id":"https://openalex.org/C178790620","wikidata":"https://www.wikidata.org/wiki/Q11351","display_name":"Organic chemistry","level":1,"score":0.0},{"id":"https://openalex.org/C521977710","wikidata":"https://www.wikidata.org/wiki/Q81163","display_name":"Polymer","level":2,"score":0.0},{"id":"https://openalex.org/C2779989194","wikidata":"https://www.wikidata.org/wiki/Q343016","display_name":"Acrylate","level":4,"score":0.0}],"mesh":[{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008032","descriptor_name":"Limbic System","qualifier_ui":"Q000502","qualifier_name":"physiology","is_major_topic":true},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008694","descriptor_name":"Methamphetamine","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D011919","descriptor_name":"Rats, Inbred Strains","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013373","descriptor_name":"Substance P","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D013373","descriptor_name":"Substance P","qualifier_ui":"Q000502","qualifier_name":"physiology","is_major_topic":true},{"descriptor_ui":"D051381","descriptor_name":"Rats","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1016/0014-2999(86)90775-2","doi":"https://doi.org/10.1016/0014-2999(86)90775-2","is_oa":false,"landing_page_url":"https://doi.org/10.1016/0014-2999(86)90775-2","pdf_url":null,"source":{"id":"https://openalex.org/S187816532","display_name":"European Journal of Pharmacology","issn_l":"0014-2999","issn":["0014-2999","1879-0712"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-d","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European Journal of Pharmacology","raw_type":"journal-article"},{"id":"pmid:2431914","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/2431914","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"European journal of pharmacology","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9391000270843506,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"sustainable_development_goals_aurora":[{"score":0.6899999976158142,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[{"id":"https://openalex.org/G1728406438","display_name":null,"funder_award_id":"DA 00869","funder_id":"https://openalex.org/F4320337347","funder_display_name":"National Institute on Drug Abuse"},{"id":"https://openalex.org/G488092088","display_name":null,"funder_award_id":"MH 40175","funder_id":"https://openalex.org/F4320337346","funder_display_name":"National Institute of Mental Health"}],"funders":[{"id":"https://openalex.org/F4320332505","display_name":"U.S. Public Health Service","ror":"https://ror.org/05xf94514"},{"id":"https://openalex.org/F4320337346","display_name":"National Institute of Mental Health","ror":"https://ror.org/04xeg9z08"},{"id":"https://openalex.org/F4320337347","display_name":"National Institute on Drug Abuse","ror":"https://ror.org/00fq5cm18"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":10,"referenced_works":["https://openalex.org/W1533868153","https://openalex.org/W1833844094","https://openalex.org/W1955589212","https://openalex.org/W1968750677","https://openalex.org/W2022395708","https://openalex.org/W2022522877","https://openalex.org/W2053745334","https://openalex.org/W2069357530","https://openalex.org/W2154463038","https://openalex.org/W4252714631"],"related_works":["https://openalex.org/W1955589212","https://openalex.org/W1536614704","https://openalex.org/W2036859592","https://openalex.org/W2503653922","https://openalex.org/W2050319861","https://openalex.org/W1987791464","https://openalex.org/W3017730418","https://openalex.org/W2072641246","https://openalex.org/W2158047218","https://openalex.org/W2004560227"],"abstract_inverted_index":null,"counts_by_year":[{"year":2026,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}